Kovack Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q2
– Sell
-2
Closed -$1K – 478
2019
Q1
$1K Buy
2
+1
+100% +$82 ﹤0.01% 450
2018
Q4
$1K Buy
+1
New +$88 ﹤0.01% 416
2017
Q3
– Sell
-5
Closed -$7K – 366
2017
Q2
$7K Buy
+5
New +$336 ﹤0.01% 364
2017
Q1
– Sell
-23
Closed -$8K – 305
2016
Q4
$8K Buy
23
+7
+44% +$427 ﹤0.01% 251
2016
Q3
$4K Sell
16
-3
-16% -$194 ﹤0.01% 255
2016
Q2
$7K Buy
+19
New +$1.16K ﹤0.01% 252

Other funds holding ABBV

Kovack Advisors's ABBV Position: Q3 2026 in Review

Kovack Advisors increased its AbbVie (ABBV) stake by 5.8% in Q3 2026, buying an estimated $335K and bringing the position to 23,686 shares worth $6.17M. The position accounts for 0.26% of the portfolio, ranked #66.

Kovack Advisors first reported a position in ABBV in Q3 2015 and has held it in 44 quarters since. The position peaked at $7.06M in Q4 2025. 4,285 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Kovack Advisors held 23,686 shares of AbbVie worth $6.17M as of Q3 2026.
  • Kovack Advisors bought 1,306 AbbVie shares in Q3 2026, an estimated $335K.
  • AbbVie made up 0.26% of Kovack Advisors's portfolio in Q3 2026, its #66 holding.
  • Kovack Advisors first reported a position in AbbVie in Q3 2015 and has held it in 44 quarters since.
  • Kovack Advisors's AbbVie position peaked at $7.06M in Q4 2025.
  • 4,285 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Kovack Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.